MCA Stability Tool

Zidovudine not adversely affected by short-term exposure to heat and sunlight. Capsules may become discolored or brittle and should be protected from light, heat, and moisture.

Provenance

This compatibility recommendation is derived from Retrovir 100mg capsules (ViiV Healthcare UK Ltd)

Use with caution

Zidovudine 250mg capsules (Milpharm Ltd)

Explore other Zidovudine formulations Explore other Zidovudine 250mg capsules suppliers

Stability Notes

Zidovudine not adversely affected by short-term exposure to heat and sunlight. Capsules may become discolored or brittle and should be protected from light, heat, and moisture.

Provenance

This compatibility recommendation is derived from Retrovir 250mg capsules (ViiV Healthcare UK Ltd)

Use with caution

Zidovudine 300mg / Lamivudine 150mg tablets (Milpharm Ltd)

Explore other Zidovudine + Lamivudine formulations Explore other Zidovudine 300mg / Lamivudine 150mg tablets suppliers

Stability Notes

Protect from light and store in an airtight container.

Provenance

This compatibility recommendation is derived from Combivir 150mg/300mg tablets (ViiV Healthcare UK Ltd).

Use with caution

Zidovudine 300mg / Lamivudine 150mg tablets (Viatris UK Healthcare Ltd)

Explore other Zidovudine + Lamivudine formulations Explore other Zidovudine 300mg / Lamivudine 150mg tablets suppliers

Stability Notes

Protect from light and store in an airtight container.

Provenance

This compatibility recommendation is derived from Combivir 150mg/300mg tablets (ViiV Healthcare UK Ltd).

Use with caution

Zimovane 7.5mg tablets (Sanofi)

Explore other Zopiclone formulations Explore other Zopiclone 7.5mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane 7.5mg tablets (Sanofi) and Zopiclone 7.5mg tablets (Accord Healthcare Ltd).

Use with caution

Zinamide 500mg tablets (Genus Pharmaceuticals Ltd)

Explore other Pyrazinamide formulations Explore other Pyrazinamide 500mg tablets suppliers

Stability Notes

Store in an airtight container.

Provenance

This compatibility recommendation is derived from Zinamide 500mg tablets (Genus Pharmaceuticals Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.